Next Generation vaccines

Abera is developing the next generation vaccines and immunotherapies based on our proprietary vaccine delivery platform.

hexa-02 copy
Laboratory blue

Technology

Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune system.

cdc-ruFBkCruBVk-unsplash-

Vaccine targets

Abera develops vaccine candidates based its technology – BERA. The main candidate is a universal pneumococcal vaccine candidate and the company explores applications in immunotherapy.

Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.

Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.

pexels-edward-jenner-4033020

Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.

Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.

hexa-03

NEWS

Flaggningsmeddelande

Magnus Linderoth har förvärvat aktier i Abera Bioscience AB (”Abera” eller ”Bolaget”) och därmed passerat 5% ägande. Magnus Linderoth har meddelat bolaget att han kontrollerar

Read More »

Abera is dedicated to the development of novel vaccines to save lives and increase health globally.

hexa-02 copy